(NASDAQ: LUMO) Lumos Pharma's forecast annual revenue growth rate of 112.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Lumos Pharma's revenue in 2023 is $1,737,000.On average, 3 Wall Street analysts forecast LUMO's revenue for 2023 to be $10,178,152, with the lowest LUMO revenue forecast at $9,734,936, and the highest LUMO revenue forecast at $11,080,415. On average, 2 Wall Street analysts forecast LUMO's revenue for 2024 to be $6,450,384, with the lowest LUMO revenue forecast at $3,165,833, and the highest LUMO revenue forecast at $9,734,936.
In 2025, LUMO is forecast to generate $159,755,838 in revenue, with the lowest revenue forecast at $9,734,936 and the highest revenue forecast at $309,776,739.